NCT03796910 - A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy Volunteers | Biotech Hunter

Enrollment

96

Participants

Timeline

Start Date

December 18, 2018

Primary Completion Date

September 24, 2019

Study Completion Date

September 24, 2019

Conditions

Healthy Volunteers

Interventions

DRUG

SPR720 for SAD

Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered as a single dose.

DRUG

Placebo for SAD

Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally as a single dose.

DRUG

SPR720 for MAD

Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing.

DRUG

Placebo for MAD

Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing

Trial Locations (1)

CF48 4DR

Simbec Research, Ltd., Merthyr Tydfil